An Injectable Solution for Preservation of Hematopoietic Stem and Progenitors Cells in Hypothermic Condition.
CHEVALEYRE, Jean
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
RODRIGUEZ, Laura
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
ATTEBI, Esther
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
See more >
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
CHEVALEYRE, Jean
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
RODRIGUEZ, Laura
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
ATTEBI, Esther
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
DUCHEZ, Pascale
Institut National de la Santé et de la Recherche Médicale [INSERM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
IVANOVIC, Zoran
Université de Bordeaux [UB]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
< Reduce
Université de Bordeaux [UB]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Laboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Language
EN
Article de revue
This item was published in
Stem Cell Reviews and Reports. 2024-12-12, vol. 21, n° 1, p. 96-106
English Abstract
To ensure the preservation of functional hematopoietic stem cells (HSC) and committed progenitor cells (HPC) at + 4 °C in ex vivo expanded cord blood cell products during worldwide transportation and subsequent infusion-without ...Read more >
To ensure the preservation of functional hematopoietic stem cells (HSC) and committed progenitor cells (HPC) at + 4 °C in ex vivo expanded cord blood cell products during worldwide transportation and subsequent infusion-without the need for washing and cell concentration-we developed a conservation medium called Stabilizer of Expanded Cells (SEC), composed exclusively of injectable pharmacological products. The in vivo engraftment assay in immunodeficient mice was used to detect primitive HSCs before and after preservation at + 4 °C. In some experiments, a complex phenotype based on CD34, CD38, and CD133 expression was utilized for this purpose. Committed progenitors (CFU-GM, BFU-E, and CFU-Mix) were detected using methylcellulose culture colony-forming assays. Additionally, in some cases, the energetic metabolism (mitochondrial respiration) was evaluated using Seahorse technology. SEC was able to preserve the functionality of HSCs and HPCs in ex vivo expanded cell populations at + 4 °C for at least 48 h. Furthermore, SEC is also effective in fully preserving HSCs and HPCs in cytapheresis products for at least 72 h. Additionally, SEC enabled the full preservation of HSCs and HPCs for 72 h in freshly collected cord blood, maintaining a normal metabolic profile of CD34 cells. The SEC medium exhibits a positive effect on the maintenance of both HSCs and HPCs at + 4 °C, regardless of their source. Therefore, SEC can be applied in cell therapy protocols based on HSCs and HPCs with a significant advantage: the product does not need to be washed and concentrated before injection into the patient.Read less <
English Keywords
Cell conservation
Hematopoietic stem cells
Hematopoietic progenitors
Ex vivo expansion
Cord blood
Peripheral blood